Nephrocare Health Services Ltd
Nephrocare Health Services Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #14 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
Focus on platform-level ROCE-accretive investments rather than country-level details; currently in 5 countries, aiming for 10-15 countries in 5-10 years. Nephrocare Health Services Limited maintains a medium-term growth guidance of 15% to 20% CAGR over the next 3 to 5 years.
From Nephrocare Health Services Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
2 more points from Nephrocare Health Services Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Nephrocare Health Services Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure for Q1 FY27 was INR44 crores towards center acquisitions and growth.
- The company intends to open 40 to 50 clinics in India and 10 to 15 clinics in the Philippines every year.
- Plans to enter a new international market every 12 to 18 months.
- Focus on disciplined capital allocation ensuring investments are ROCE accretive at the platform level.
- Current investments include expanding the network, pursuing center acquisitions in both India and international markets, and paying off term loans.
2 more points from Nephrocare Health Services Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Nephrocare Health Services Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Nephrocare Health Services Ltd's call on order book
Create a free account to keep reading this call
Nephrocare Health Services Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹266 Cr, net profit ₹30 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Nephrocare Health Services's management said in earlier quarters
Others in Healthcare Services this season
- Aatmaj Health (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital Ltd (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Nephrocare Health Services Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Nephrocare Health Services Ltd Q1 FY27 results?
Focus on platform-level ROCE-accretive investments rather than country-level details; currently in 5 countries, aiming for 10-15 countries in 5-10 years. Nephrocare Health Services Limited maintains a medium-term growth guidance of 15% to 20% CAGR over the next 3 to 5 years.
What is Nephrocare Health Services Ltd share price analysis?
Nephrocare Health Services Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 82.0 with a market cap of ₹6,980 Cr. Investors should review the full earnings analysis for detailed insights.
Is Nephrocare Health Services Ltd planning capital expenditure?
Capital expenditure for Q1 FY27 was INR44 crores towards center acquisitions and growth.
Keep Nephrocare Health Services Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
